Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior treatment with an immune checkpoint inhibitor, and fewer than anticipated adverse events, according to results from a phase Ib clinical trial presented here...
Tag: <span>Immunotherapy</span>
Post
Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or...
Post
Study provides path for new immunotherapy approaches to prostate cancer
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine. Based...
Post
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Introduction Metastatic cancers remain an incurable disease for the great majority of patients, as the intrinsic genomic instability common to all cancers facilitates the escape from cytotoxic or targeted therapies. The recent breakthroughs in the understanding of tumor immune biology and the development of newer generation of cancer immunotherapies have opened a brand new chapter...
Post
Scientists reveal potential way of boosting immune system's memory to fight cancer
Scientists from the University of Southampton have discovered an important way that the immune system can learn to recognize and fight cancers. The team, led by Professor Aymen Al-Shamkhani and funded by Cancer Research UK, has shown that a protein called Akt, is vital for the way the body remembers a cancer it has eradicated....
Post
Two babies with terminal cancer CURED after 'miracle' treatment
Two British infants, 11 and 16 months old, have been cured of leukemia Both have been in remission for at least a year post-treatment London doctors used genetically engineered immune cells to treat the cancer This could lead to off-the-shelf cellular therapy at a low cost for future patients Two babies who were...
Post
The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors
And prolongs survival for patients with bladder cancer Amsterdam, The Netherlands: Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings were presented in two presentations at the European Cancer Congress 2017...
Post
Bodywide immune response important for fighting cancer, researchers say
Edgar Engleman and his colleagues have found that a systemwide immune response is needed to effectively attack a tumor. Fighting off cancer requires the concerted efforts of immune molecules throughout the body, rather than just in the tumor itself, according to a new study of laboratory mice by researchers at the Stanford University School of...
Post
Immunotherapy, gene therapy combination shows promise against glioblastoma
“Devastating” and “dismal.” That’s how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months. New research out of the University of Michigan supports combining two approaches to fight back against gliomas: attacking the tumor with gene therapy while...
Post
FDA To Speed Up Review Of Roche Tecentriq As Immunotherapy Treatment For Bladder Cancer
Swiss pharmaceutical company Roche has announced that U.S. health regulators have agreed to grant priority review to its Tecentriq immunotherapy treatment for a type of bladder cancer. In a statement, the drug company said that the U.S. Food and Drug Administration has accepted its Biologics License Application, or BLA, and agreed to priority-review the treatment. Tecentriq Tecentriq (atezolizumab)...